China Molecular Diagnostics Market (2025-2030)
The China Molecular Diagnostics Market was valued at $1067.1 Million in 2025 and projected to reach to $2021.3 Million by 2030, representing a compound annual growth rate of 13.6%. China's molecular diagnostics market is positioned for sustained high-growth expansion through 2030, supported by increasing healthcare expenditure, technological advancement, and government initiatives promoting precision medicine.
China Molecular Diagnostics Market Trends and Insights
- This represents a compound annual growth rate of 13.6%, significantly outpacing global market growth of 9.6%.
- China's rapid advancement is driven by increasing healthcare investments, rising prevalence of infectious diseases, and growing adoption of precision medicine across urban and rural healthcare systems. The molecular diagnostics sector in China benefits from government initiatives promoting genomic research and personalized medicine.
- China's expanding middle class and improved healthcare accessibility are accelerating demand for advanced diagnostic solutions.
- Between 2025 and 2030, China is expected to consolidate its position as a leading molecular diagnostics market in Asia Pacific, supported by technological innovation and regulatory framework improvements that facilitate faster market entry for diagnostic platforms. China's molecular diagnostics market reflects the country's commitment to modernizing its healthcare infrastructure and enhancing disease detection capabilities.
- The forecast period through 2030 will likely see intensified competition among domestic and international players seeking to capture China's growing diagnostic demand..
Key Market Statistics
- CAGR (2025-2030) 13.6% CAGR
- Market Size, 2025 ~USD 1067.1 Million
- Forecast, 2030 ~USD 2021.3 Million
- Country China
China Molecular Diagnostics Market Overview
Exceptional Growth Trajectory :
China's molecular diagnostics market is expanding at 13.6% CAGR, significantly outpacing the global rate of 9.6%, driven by substantial government healthcare investments and modernization of diagnostic infrastructure across urban and rural regions.
Market Valuation Surge :
The market is valued at USD 1,067.1 million in 2025 and is projected to nearly double to USD 2,021.3 million by 2030, reflecting strong demand for advanced diagnostic solutions and increased healthcare spending in the world's second-largest economy.
Disease Prevalence Drivers :
Rising prevalence of infectious diseases, including COVID-19 variants, tuberculosis, and hepatitis, combined with growing cancer incidence, is accelerating adoption of molecular diagnostic tests across Chinese hospitals and diagnostic centers.
Healthcare Infrastructure Expansion :
China's commitment to universal healthcare coverage and expansion of diagnostic capabilities in tier-2 and tier-3 cities is creating substantial opportunities for molecular diagnostics providers and technology suppliers.
China Molecular Diagnostics Market Dynamics
- The market's 13.6% CAGR reflects strong demand from both public healthcare systems and private diagnostic laboratories seeking advanced testing capabilities. Key growth catalysts include rising disease burden, aging population demographics, and integration of molecular diagnostics into routine clinical practice.
- Investment in R&D, regulatory streamlining for diagnostic approvals, and growing awareness among healthcare providers and patients will further accelerate market penetration across China's diverse geographic regions..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Stryker Corporation
- Abbott Laboratories
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- China's molecular diagnostics market will nearly double from USD 1,067.1M (2025) to USD 2,021.3M (2030), driven by 13.6% CAGR growth.
- China's market growth rate of 13.6% significantly exceeds the global average of 9.6%, positioning China as a high-growth regional leader.
- Government healthcare initiatives and precision medicine adoption are accelerating molecular diagnostics demand across China's healthcare system.
- China's expanding healthcare infrastructure and rising disease prevalence create sustained opportunities for diagnostic innovation through 2030.
Molecular Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | HEPATITIS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.6% from 2025 to 2030 |
| Largest Segment | LAB TESTS (Test Type) |
| Market Size Base Year (Billions) | ~USD 19.44 (2025) |
| Revenue Forecast (Billions) | ~USD 30.74 (2030) |
| Segments Covered | Product & Service, Test Type, Sample Type, Type |
China Molecular Diagnostics Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Kits
- Services & Software
By Test Type
- Lab Tests
- Poc Tests
By Sample Type
- Blood, Serum & Plasma
- Other Sample Types
- Urine
By Type
- Breast Cancer
- Colorectal Cancer
- Influenza
- Lung Cancer
- Other Cancers
- Other Respiratory Infectious Diseases
- Pharyngitis
- Prostate Cancer
- Tuberculosis
Target Audience
- In Vitro Diagnostics (IVD) Manufacturers : Manufacturers need China-specific market data to develop localized product strategies, understand regulatory pathways, and identify distribution partnerships in this rapidly expanding 13.6% CAGR market.
- Healthcare Investment Firms : Investment professionals require detailed China market analysis to evaluate portfolio opportunities, assess growth potential, and make informed capital allocation decisions in the molecular diagnostics sector.
- Hospital & Diagnostic Laboratory Operators : Laboratory administrators need market insights to benchmark performance, identify technology upgrade opportunities, and plan capacity expansion aligned with China's growing diagnostic demand.
- Pharmaceutical & Biotech Companies : Companies developing companion diagnostics and precision medicine solutions need China-specific market data to support clinical trial planning, commercialization strategies, and reimbursement negotiations.
- Healthcare Consultants & Advisors : Consulting professionals require comprehensive China market intelligence to advise clients on market entry, competitive positioning, and strategic planning in the molecular diagnostics space.
Key Companies in the China Molecular Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease and HAIs),Virology, oncology, and genetics assays, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, logistics, O&M, mission-critical facilities), |
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CODEXIS, INC. | United States | Public Company | CodeEvolver-enabled enzyme products and services,ECO Synthesis RNAi manufacturing platform (licenses, milestones, royalties),Other technology partnerships and R&D collaborations, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging,Pathology and centres of excellence, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media (clinical),Urinalysis test strips, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array instruments and consumables, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, treatment support),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| BIOMÉRIEUX | France | Public Company | |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices (cardiovascular, diabetes care, neuromodulation),Diagnostic Products (lab, molecular, point-of-care, rapid),Nutritional Products (pediatric, adult, infant formula), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant/viral load assays),Oncology and sexual and reproductive health assays, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, autoimmune),Life science reagents and assay platforms,Instruments, software, and services, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
CEPHEID INC.
Cepheid Inc. is a private U.S. diagnostic company founded in 1996 with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing solutions.
FLUOR CORPORATION
Fluor Corporation is a large U.S. engineering and construction company founded in 1912, operating as a public company with approximately 23,000 employees. The firm provides design, engineering, procurement, and construction services across multiple industries.
SANOFI
Sanofi is a major French pharmaceutical company founded in 1994 and publicly traded, with over 74,800 employees worldwide. The company develops and manufactures prescription medicines, vaccines, and consumer healthcare products.
CODEXIS, INC.
Codexis, Inc. is a publicly traded U.S. biotechnology company founded in 2002 with 146 employees. The company develops and commercializes biocatalysts and enzymes for pharmaceutical and chemical manufacturing.
UNILABS
Unilabs is a private Swiss clinical laboratory and diagnostics company founded in 1987 with 1,897 employees. The company offers laboratory testing and diagnostic services across Europe.
EIKEN CHEMICAL CO., LTD.
Eiken Chemical Co., Ltd. is a publicly traded Japanese chemical and diagnostics company founded in 1939 with 696 employees. The company manufactures diagnostic reagents, pharmaceuticals, and chemical products.
DANAHER CORPORATION
Danaher Corporation is a large publicly traded U.S. conglomerate founded in 1969 with 59,000 employees. The company operates across multiple sectors including diagnostics, life sciences, and environmental solutions.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded U.S. genomics company founded in 1998 with 8,625 employees. The company designs and manufactures DNA sequencing and array-based analysis systems.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. medical device company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and surgical products focused on women's health and oncology.
BIOMÉRIEUX
bioMérieux is a publicly traded French diagnostics company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and food safety.
ABBOTT LABORATORIES
Abbott Laboratories is a large publicly traded U.S. healthcare company founded in 1888 with 115,000 employees. The company manufactures pharmaceuticals, diagnostics, medical devices, and nutritional products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a major publicly traded U.S. life sciences company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, software, and services for research and diagnostics.
QIAGEN N.V.
QIAGEN N.V. is a publicly traded Dutch life sciences company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics, sample preparation, and bioinformatics solutions.
REVVITY, INC.
Revvity, Inc. is a publicly traded U.S. life sciences and diagnostics company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for research and diagnostics.
GRIFOLS, S.A.
Grifols, S.A. is a publicly traded Spanish pharmaceutical and diagnostics company founded in 1909 with 25,000 employees. The company specializes in plasma-derived medicines, transfusion medicine, and diagnostics.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for China (USD 1,067.1M in 2025) with verified 13.6% CAGR projections through 2030, enabling accurate financial forecasting and investment decision-making in this high-growth market.
- Competitive Landscape Intelligence : Understand China-specific competitive dynamics, key market players, and their strategic positioning within the molecular diagnostics sector to identify partnership opportunities and market entry strategies.
- Regional Growth Drivers Analysis : Gain insights into China-specific growth catalysts including healthcare policy changes, disease prevalence trends, and infrastructure development that differentiate this market from global trends.
- Regulatory & Reimbursement Insights : Access detailed information on China's diagnostic approval processes, reimbursement policies, and healthcare system requirements essential for product commercialization and market penetration strategies.
- Strategic Market Segmentation : Identify high-opportunity segments within China's molecular diagnostics market by disease type, end-user, technology platform, and geography to optimize resource allocation and targeting strategies.
Frequently asked questions
What is the projected size of China's molecular diagnostics market in 2030?
China's molecular diagnostics market is projected to reach USD 2,021.3 million by 2030, nearly doubling from its 2025 valuation of USD 1,067.1 million.
What is the CAGR for China's molecular diagnostics market?
China's molecular diagnostics market is expected to grow at a compound annual growth rate of 13.6% between 2025 and 2030.
How does China's market growth compare to global trends?
China's molecular diagnostics market CAGR of 13.6% significantly outpaces the global market CAGR of 9.6%, reflecting China's accelerated adoption of diagnostic technologies.
What factors are driving growth in China's molecular diagnostics market?
Key growth drivers in China include government healthcare investments, rising infectious disease prevalence, expanding precision medicine adoption, and improved healthcare accessibility across urban and rural regions.
What is the current market size of molecular diagnostics in China?
In 2025, China's molecular diagnostics market is valued at USD 1,067.1 million, establishing a strong baseline for continued expansion through 2030.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global molecular diagnostics market. Exhaustive secondary research was done to collect information on the molecular diagnostics market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the molecular diagnostics market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to, to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources mainly include industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Breakdown Of Primary Participants
Note 1: Others include Sales Managers, Marketing Managers, and Product Managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers:
Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in the market.
- The key players in the industry have been identified through extensive secondary research.
- Primary and secondary research have determined the revenues generated by leading players operating in the molecular diagnostics market.
- All percentage share, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global molecular diagnostics market by product & service, test type, sample type, technology, application, technique, clinical application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze the micromarkets concerning individual growth trends, prospects, and contributions to the overall molecular diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market with respect to five regions, namely North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments, such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the molecular diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the molecular diagnostics market, along with the macroeconomic outlook for each region
Get the Full Molecular Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Molecular Diagnostics Market.
- Canada Molecular Diagnostics Market
- US Molecular Diagnostics Market
- Germany Molecular Diagnostics Market
- UK Molecular Diagnostics Market
- France Molecular Diagnostics Market
- Italy Molecular Diagnostics Market
- Spain Molecular Diagnostics Market
- Russia Molecular Diagnostics Market
- Switzerland Molecular Diagnostics Market
- Japan Molecular Diagnostics Market
- India Molecular Diagnostics Market
- Australia Molecular Diagnostics Market
- South Korea Molecular Diagnostics Market
- Brazil Molecular Diagnostics Market
- Mexico Molecular Diagnostics Market
- Saudi Arabia Molecular Diagnostics Market
- UAE Molecular Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report